Cancer Immunotherapy Group Publications
Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F, Hermans IF Potent anti-tumour responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol, 2010 Feb 9 [Epub ahead of print]
Dickgreber N, Stoitzner P, Bai Y, Price KM, Farrand KJ, Manning K, Angel CE, Dunbar PR, Ronchese F, Fraser JD, Bäckström BT, Hermans IF (2009) Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy. J Immunol, 182:1260-9
Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF (2009) Langerin+CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. J Immunol, 183:7732-42
Robinson MJ, Ronchese F, Miller JH, La Flamme AC (2009) Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro. Immunol Cell Biol, [Epub ahead of print 8 Dec 2009]
Tripp CH, Sparber F, Hermans IF, Romani N, Stoitzner P (2009) Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells. J Immunol, 182:7644-54
Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF, Ritchie DS, Yang J, Ronchese F (2008) Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol, 181:8356-62
Huck SP, Tang S-C, Andrew KA, Yang J, Harper JL, Ronchese F (2008) Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumours. Cancer Immunol Immunother, 57:63-71
Peacey M, Wilson S, Perret R, Ronchese F, Ward VK, Young V, Young SL, Baird MA (2008) Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine, 26:5334-7
Perret R, Ronchese F (2008) Effector CD8(+) T cells activated in vitro confer immediate and long-term tumor protection in vivo. Eur J Immunol, 38:2886-95
Perret R, Ronchese F (2008) Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens, 72:187-94
Stoitzner P, Green LK, Jung JY, Price KM, Ataera H, Kivell B, Ronchese F (2008) Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother, 57:1665-73
Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F (2008) Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J Immunol, 180:1991-8
Huck S (2007) Report from the ANZSLAS Conference. NAEAC News, Issue 25: p8
Matthews KE, Karabeg A, Roberts JM, Saeland S, Dekan G, Epstein MM, Ronchese F (2007) Long-term deposition of inhaled antigen in lung resident CD11b-CD11c+ Cells. Am J Respir Cell Mol Biol, 36:435-41
Matthews KE, Qin JS, Yang J, Hermans IF, Palmowski MJ, Cerundolo V, Ronchese F (2007) Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses. J Immunol, 179:5738-47
Pedersen AE, Ronchese F (2007) CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion. J Immune Based Ther Vaccines 5:9
Watt V, Ronchese F, Ritchie DS (2007) Resting B lymphocytes suppress tumour immunity via an MHC class-II dependent mechanism. J Immunother, 30:323-32
Matthews KE, Hermans IF, Roberts JM, Ching LM and Ronchese F (2006) DMXAA treatment of a non-immunogenic tumour does not synergise with active or passive CD8+ T cell immunotherapy. Immunol Cell Biol, 84:383-9
Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson E, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA, 103:1132-37
Ritchie D, Hermans I, Yang J, Walton J, Matthews K, Carter J, Findlay M, Dady P, Rawson P, Ronchese F (2006) Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma. 47:675-82
Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L, Ronchese F, Romani N (2006) Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA. 103:7783-8
Yang J, Huck SP, McHugh RS, Hermans IF and Ronchese F (2006) Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci USA, 103:147-52
Harris NL, Holloway J, Fitzharris P, McDonald M, Camberis M, Fazekas de St Groth B, Ronchese F, Le Gros G (2005) Tissue localization and frequency of antigen-specific effector CD4 T cells determines the development of allergic airway inflammation. Immunol Cell Biol. 83:490-7
Kemp R, Bäckström T, Ronchese F (2005) The phenotype of Type 1 and Type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunology, 115(3):315-24
Prasad S, Farrand K, Matthews S, Chang J, McHugh R, Ronchese F (2005) Dendritic cells loaded with stressed tumor cells elicit long lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol, 174:90-98
van Panhuys N, Perret R, Prout M, Ronchese F, Le Gros G (2005) Effector Lymphoid Tissue and its critical role for protective immunity. Trends in Immunol. 26(5):242-7
Facchinetti A, Gallo P, Perini P, Mezzalira S, Ronchese F, Biasi G (2004) The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigens. J. Neuroimmunol, 148:154-61
Hermans I, Silk J, Yang J, Gileadi U, Palmowski M, McCarthy C, Ronchese F, Cerundolo V (2004) The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods, 285:25-40
Ritchie DS, Yang J, Hermans IF, Ronchese F (2004) B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumor immune response by direct and indirect activation of CD8+ T-cells. Scand J Immunol, 60:543-51
Roberts JM, Yang J, Ronchese F (2004) IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo. Int. Immunol. 16:1451-58
Lumsden, JM, Prasad SJ, Peach RJ, Ronchese F (2003) The effects of B7-dependent costimulation on T cell division and survival in vivo and in vitro are dependent on Ag concentration. Eur J Immunol. 33:2074-2082
Harris N, Watt V, Ronchese, F, Le Gros, G. 2002. Differential T cell function and fate in lymph node and non-lymphoid tissues. J. Exp. Med., 195:317-26.
Ronchese F (2002) Interview about killing of dendritic cells. Modern Aspects of Immunobiology, 2:100
Ronchese F, Prasad S, Ritchie D (2002) Tumour antigens on tap. The Lancet, 360:268
Chtanova T, Kemp R, Sutherland A, Ronchese F, Mackay C (2001) Gene microarrays reveal extensive differential gene expression in both CD4+ and CD8+ type 1 and type 2 T cells. J Immunol, 167:3057-63
Kemp RA, Ronchese F (2001) Tumor-specific Tc1 but not Tc2 cells deliver protective anti-tumor immunity. J Immunol, 167:6497-6502
Harris N, Prout M, Peach R, Fazekas de St Groth B, Ronchese F (2001) CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung. J Immunol, 166:4908-14
Ronchese F, Hermans I (2001) Killing of dendritic cells: a life cut short, or a purposeful death? J Exp Med, 194: F23-6
Hermans I, Ritchie D, Roberts J, Yang J, Ronchese F (2000) CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of anti-tumor immunity. J Immunol, 164:3095-101
Lumsden J, Roberts J, Harris N, Peach R, Ronchese F (2000) Differential requirement for CD80 and CD80/CD86 dependent costimulation in the lung immune response to an influenza virus infection. J Immunol, 164:79-85
Rawson P, Hermans I, Huck S, Roberts J, Pircher H, Ronchese, F (2000) Immunotherapy with dendritic cells and tumor MHC Class I-derived peptides requires high density of antigen on tumor cells. Cancer Res, 60:4493-98
Ritchie D, Hermans I, Lumsden J, Scanga C, Roberts J, Yang J, Kemp R, Ronchese F, (2000) Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Meth, 246:109-17
Harris N, Peach R, Ronchese F (1999) CTLA4-Ig inhibits optimal T helper 2 cell development but not protective immunity or memory response to Nippostrongylus brasiliensis. Eur J Immunol, 29, 311-316
Harris N, Ronchese F (1999) The role of B7 co-stimulation in T cell immunity. Immunol Cell Biol, 77: 304-311
Hermans I, Ritchie D, Daish A, Yang J, Kehry M, Ronchese F (1999) Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. J Immunol, 163:77-81
McCoy K, Hermans I, Fraser H, Le Gros G, Ronchese F (1999) Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8+ T cells independently of CD4+ T cell help. J Exp Med, 189:1157-62
Hermans I, Daish A, Yang J, Ritchie D, Ronchese F (1998) Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res, 58:3909-17
Hermans I, Moroni-Rawson P, Ronchese F, Ritchie D (1998) The emerging role of the dendritic cell in novel cancer therapies. New Zeal Med J 111:111-113
Le Gros G, Erb K, Harris N, Holloway J, McCoy K, Ronchese, F (1998) Immunoregulatory networks in asthma. Clinical & Exp Allergy vol 28, suppl 5, 92-96
Harris N, Campbell C, Le Gros G, Ronchese F (1997) Blockade of CD28/B7 co-stimulation by mCTLA4-H1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur J Immunol, 27:155-161
Harris N, Peach R, Naemura J, Linsley P, Le Gros G, Ronchese F (1997) CD80 co-stimulation is essential for the induction of airway eosinophilia. J Exp Med, 185:177-82
Hermans I, Daish A, Moroni-Rawson P, Ronchese F (1997) Tumor-peptide pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol Immunother, 44:341-47
Ronchese, F (1997) New strategies for tumour immunotherapy. NZ Science Review, 54:53-57
Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J, Ronchese F (1996) Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood, 88:3508-12.
